

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of Cayman Islands with limited liability)

(Stock Code: 6833)

INSIDE INFORMATION

This announcement is made by Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**” and each a “**Director**”) of the Company hereby informs shareholders of the Company and potential investors that, on 15 September 2022, the Company received a letter from Ernst & Young (“**EY**”), being the auditors of the Company, informing that there may be possible internal control irregularities (“**Incident**”), which may probably be unauthorized transactions, during the six months ended 30 June 2022.

Even though the relevant amount under the unauthorized transactions has been recovered as at the date hereof and the Company has not suffered any financial loss, the Board has, on 17 September 2022, resolved to establish an independent investigation committee (the “**Independent Committee**”), initially comprising four independent non-executive Directors, namely Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong, for the purpose of, among other things, investigating into the Incident. The Independent Committee may also appoint other professional advisers to assist in its investigation. The Company will update its shareholders and investors the progress and the results of the investigation as and when appropriate.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 26 September 2022

As at the date of this announcement, the executive Director is Mr. Huang Xiangbin; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.